| Technology Platform - TheraPlas™ |
|
Currently EGEN is developing gene-based biopharmaceuticals that rely on proprietary delivery technologies to create products that are safe, effective and well-characterized. In preclinical studies the application of this approach has produced significant results for the treatment of disseminated abdominal cancers, solid tumors and metastatic cancers.
 |
| Next > |
|---|